No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
12 – 18
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Children's Hospital Los Angeles · Other
Who this trial is looking for
This trial is looking for young people aged 12 to 18 who have severe obesity and are undergoing weight loss surgery. Participants will take a medication called semaglutide or receive standard care for two years after surgery.
Are You a Good Fit for This Trial?
Must be takingSemaglutide
Rules you outType 1 diabetes
You may be able to join if
I am between 12 and 18 years old
I have severe obesity
I am undergoing weight loss surgery
I have been taking semaglutide 2.4 mg weekly before surgery
I am willing to have blood collected before and after surgery
I have a consenting caregiver
I am in Tanner stage 3 or higher
You may not be able to join if
I have a previous diagnosis of type 1 diabetes
I take medications that affect weight
I have been diagnosed with certain syndromes affecting surgery
I have significant medical conditions requiring frequent hospitalization
I refuse to comply with eligibility criteria
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1…
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* ages 12 to 18 years
* Tanner stage 3 or higher
* severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)
* currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
*…
Inclusion Criteria:
* ages 12 to 18 years
* Tanner stage 3 or higher
* severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)
* currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
* be willing to have blood collected before and after surgical procedure at defined points
* be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver
* be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.
Exclusion Criteria:
* have a previous diagnosis of type 1 diabetes
* taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)
* have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)
* have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities
* refuse to comply with eligibility criteria.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.